Möchten Sie immer auf dem neuesten Stand bleiben?

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Data Center Chip Market Report by Chip Type, Data Center Size, Industry Vertical, and Region 2026-2034" has been added to ResearchAndMarkets.com's...

Significant improvements in pain, function and patient global outcomes demonstratedLEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE...

Schindellegi, Switzerland – 30 March 2026 Trifork Group AGCompany announcement no. 22/2026 Weekly report on share buyback On 27 February 2026, Trifork initiated a share buyback program in...

Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO CapitalTetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals,...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...

Miami, Florida, March 27, 2026 (GLOBE NEWSWIRE) -- The Arm Confidence Problem That Nobody Talks About There is a conversation happening in dressing rooms, group chats, and doctors' offices...

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.